ReviewDrugs2015
Ruxolitinib: a review of its use in patients with myelofibrosis.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review.Clinical pharmacokinetics · 2023Pooled it
- Next-generation Janus kinase inhibitors: Integrating synthetic innovation, structural biology, and computational design for precision drug discovery.Pharmaceutical science advances · 2026Review
- CAMK2D causes heart failure in mice with RBM20 cardiomyopathy.Nature cardiovascular research · 2026Article
- Assessing pharmacokinetics and drug-drug interactions of the combination therapy of myelofibrosis with ruxolitinib and lenalidomide by a new eco-friendly HPLC method for their simultaneous determination in plasma.Cancer chemotherapy and pharmacology · 2024Article
- JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions.Molecular diversity · 2024Review
- A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.Targeted oncology · 2024Article
- Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.Oncotarget · 2024Article
- Discovery ofACS medicinal chemistry letters · 2023Article
- An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor.Science translational medicine · 2023Article
- JAK/STAT signaling in diabetic kidney disease.Frontiers in cell and developmental biology · 2023Review
- JAK: Not Just Another Kinase.Molecular cancer therapeutics · 2022Review
- Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology.American journal of physiology. Cell physiology · 2022Review
- Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.Platelets · 2022Article
- SLAMF7 engagement superactivates macrophages in acute and chronic inflammation.Science immunology · 2022Article
- Momelotinib: an emerging treatment for myelofibrosis patients with anemia.Journal of hematology & oncology · 2022Review
- Cardiac complications in a patient affected by systemic mastocytosis and primitive myelofibrosis: A case report.Clinical case reports · 2021Article
- JAK/STAT Activation: A General Mechanism for Bone Development, Homeostasis, and Regeneration.International journal of molecular sciences · 2020Review
- COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus.European journal of medicinal chemistry · 2020Review
- Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates.Molecules (Basel, Switzerland) · 2020Review
- Ruxolitinib protects lipopolysaccharide (LPS)-induced sepsis through inhibition of nitric oxide production in mice.Annals of translational medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ruxolitinib (Jakavi(®), Jakafi(®)) is an orally administered inhibitor of Janus kinases (JAK) 1 and 2 used in the management of patients with myelofibrosis. Clinical trials with ruxolitinib, notably the phase III COMFORT-I and -II studies and their extensions, have demonstrated marked and durable clinical benefits in terms of reductions in splenomegaly and disease-related symptoms in patients with intermediate-2 or high-risk myelofibrosis. Ruxolitinib was also associated with improvements in health-related quality of life and functioning. Despite the crossover of patients in control groups to ruxolitinib, results of the COMFORT studies and their extensions indicate a survival advantage for patients randomized to ruxolitinib. The beneficial effects of ruxolitinib were observed across subgroups of myelofibrosis patients, including those not harbouring the JAK2V617F mutation. Improvements in splenomegaly and disease-related symptoms were also observed in a trial in Japanese/Asian patients with myelofibrosis and in myelofibrosis patients with a low baseline platelet count. Dose-related anaemia and thrombocytopenia were common in clinical trials with ruxolitinib, but rarely led to discontinuation of therapy and were managed with dosage modifications and/or transfusions of packed red blood cells. In addition to the USA and EU, ruxolitinib is now approved in a number of other countries, including Japan, and remains the only approved drug for the treatment of myelofibrosis, although various other agents are undergoing investigation. Appropriate monitoring and dosage titration are important to achieve optimal clinical benefits of ruxolitinib. Further research, including studies evaluating ruxolitinib-based combination therapy, may also help to optimise treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.